uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

QURE uniQure N.V.

交易中 01-14 12:11:00 EST

22.26

+0.76

+3.53%

最高22.54	最低21.15	成交量60.64万
今开21.53	昨收21.50	日振幅6.47%
总市值13.87亿	流通市值9.05亿	总股本6,229万
成交额1,330万	换手率1.49%	流通股本4,064万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure N.V.","latestPrice":22.26,"timestamp":1768410646389,"preClose":21.5,"halted":0,"volume":606409,"delay":0,"floatShares":40636300,"shares":62291663,"eps":-4.344329,"marketStatus":"交易中","change":0.76,"latestTime":"01-14 12:11:00 EST","open":21.53,"high":22.54,"low":21.15,"amount":13304586.171595002,"amplitude":0.064651,"askPrice":22.31,"askSize":60,"bidPrice":22.26,"bidSize":43,"shortable":3,"etf":0,"ttmEps":-4.344329,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1768424400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":21.5,"preHourTrading":{"tag":"盘前","latestPrice":21.48,"preClose":21.5,"latestTime":"09:25 EST","volume":1634,"amount":35232.098848,"timestamp":1768400700036},"postHourTrading":{"tag":"盘后","latestPrice":21.54,"preClose":21.5,"latestTime":"19:27 EST","volume":26421,"amount":569052.4901,"timestamp":1768350478283},"volumeRatio":0.554158,"impliedVol":0.8295,"impliedVolPercentile":0.4064},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"1136475398","title":"异动解读 | 监管挑战致uniQure股价盘中大跌8.82%，AMT-130药物前景不明","url":"https://stock-news.laohu8.com/highlight/detail?id=1136475398","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136475398?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:03","pubTimestamp":1762787003,"startTime":"0","endTime":"0","summary":"周一盘中，生物技术公司uniQure N.V.股价大跌8.82%，主要原因是其用于治疗亨廷顿病的AMT-130药物面临监管挑战。尽管如此，uniQure管理层表示仍然相信AMT-130的潜力，并计划与FDA紧密合作推进该项目。除AMT-130外，uniQure的其他项目如AMT-260和AMT-191显示出早期临床进展，预计2026年会有更新数据。截至报告期末，uniQure拥有6.492亿美元现金储备，预计可支持运营至2029年。尽管公司整体财务状况稳健，但AMT-130的监管不确定性仍然是投资者关注的焦点，这也是导致股价大跌的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"gpt_icon":0},{"id":"1135225871","title":"uniQure 2025年第三季度业绩会总结及问答精华：AMT-130的监管挑战与未来展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1135225871","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135225871?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:01","pubTimestamp":1762786875,"startTime":"0","endTime":"0","summary":"公司仍然相信AMT-130的潜力，并计划与FDA紧密合作以推进该项目。研发费用增加至3440万美元，反映了AMT-130的BLA准备工作。现金储备为6.492亿美元，预计可支持运营至2029年。问题1：AMT-130的外部对照组是如何构建的？患者和医生社区对AMT-130充满期待，并积极合作推动项目进展。管理层对AMT-130的潜力充满信心，但对FDA的反馈表示失望和意外。AMT-162项目因剂量限制毒性暂停，需进一步评估。uniQure在2025年第三季度面临重大监管挑战，特别是AMT-130在亨廷顿病项目上的不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"gpt_icon":0},{"id":"1175225490","title":"uniQure盘初暴跌60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175225490","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175225490?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:44","pubTimestamp":1762181057,"startTime":"0","endTime":"0","summary":"周一，基因治疗公司 $uniQure N.V.(QURE)$ 暴跌60%。据报道，FDA表示该公司的一项重要症治疗方案的临床数据未达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"64989c908af4d31938f65fabf9403946","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"gpt_icon":0},{"id":"1196508406","title":"uniQure N.V.在美上市股票盘前下跌66.2%，因FDA称其亨廷顿舞蹈症治疗临床数据不足","url":"https://stock-news.laohu8.com/highlight/detail?id=1196508406","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196508406?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:34","pubTimestamp":1762173298,"startTime":"0","endTime":"0","summary":"uniQure N.V.在美上市的股票在盘前交易中下跌了66.2%，原因是美国食品药品监督管理局（FDA）表示该公司的亨廷顿舞蹈症治疗方案的临床数据未达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"64989c908af4d31938f65fabf9403946","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","BK4139","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2576772599","title":"Uniqure N.V.盘中异动 临近收盘股价大跌5.01%报59.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576772599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576772599?lang=zh_cn&edition=full","pubTime":"2025-10-17 03:33","pubTimestamp":1760643232,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日03时33分，Uniqure N.V.股票出现异动，股价大幅下跌5.01%。截至发稿，该股报59.69美元/股，成交量187.013万股，换手率3.04%，振幅8.48%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.36%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139","LU0320765992.SGD","LU0889565916.HKD","PRAX","LU0109394709.USD"],"gpt_icon":0},{"id":"2574338534","title":"Uniqure N.V.盘中异动 早盘大幅下挫5.06%报60.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574338534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574338534?lang=zh_cn&edition=full","pubTime":"2025-10-10 23:29","pubTimestamp":1760110181,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日23时29分，Uniqure N.V.股票出现异动，股价大幅下跌5.06%。截至发稿，该股报60.43美元/股，成交量142.447万股，换手率2.31%，振幅5.47%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.72%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010232941a4599d8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010232941a4599d8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"2570895044","title":"Uniqure N.V.盘中异动涨3.46% 振幅达9.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570895044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570895044?lang=zh_cn&edition=full","pubTime":"2025-09-27 02:15","pubTimestamp":1758910502,"startTime":"0","endTime":"0","summary":"北京时间2025年09月27日02时15分，Uniqure N.V.股票出现波动，股价急速拉升3.46%。截至发稿，该股报54.47美元/股，成交量809.726万股，换手率14.76%，振幅9.93%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.03%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。消息层面，截至02时15分，《坎托·菲茨杰拉德维持uniQure NV买入评级，上调目标价至80美元》资讯为影响Uniqure N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092702150395476a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092702150395476a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2570887317","title":"生物技术公司uniQure将公开发行股票筹资3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570887317","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570887317?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:49","pubTimestamp":1758898140,"startTime":"0","endTime":"0","summary":"生物技术公司uniQure(QURE)早盘下跌2.6%，该公司将扩模后的3亿美元公开发行定价为每股47.50美元。所筹资金将支持公司持续进行临床试验和产品开发，巩固其在基因治疗市场的地位。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-26/doc-infrvwzm4733942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SINA","BK4139","QURE"],"gpt_icon":0},{"id":"2570033730","title":"uniQure(QURE.US)因基因疗法AMT-130大涨 高盛唱多：峰值销售额有望达25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570033730","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570033730?lang=zh_cn&edition=full","pubTime":"2025-09-26 16:37","pubTimestamp":1758875830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛最新深度分析报告聚焦uniQure NV基因疗法AMT-130在亨廷顿病治疗中的突破性进展及商业前景。近日，该股已因为该疗法消息出现大涨。商业前景方面，高盛模型预测AMT-130全球峰值销售额可达25亿美元，成功概率90%。uniQure计划初期聚焦美国约2万确诊有症状患者中的6000人进行市场推广，假设累计渗透率约25%。uniQure通过与监管机构的持续沟通及严谨的临床数据积累，正稳步推进这一创新疗法的商业化进程，为患者和投资者创造双重价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4516","LU1868836591.USD","LU1868836757.USD","LU2750360997.AUD","BK4127","BK4504","IE0004086264.USD","LU0106831901.USD","LU1894683348.USD","BK4585","BK4581","LU1894683264.USD","QURE","LU2471134796.USD","LU2471134952.CNY","LU2237443465.HKD","BK4084","LU2237443622.USD","LU2471134879.HKD","LU1668664300.SGD","LU2265009873.SGD","LU0742534661.SGD","BK4139","LU0251131958.USD","BK4554","LU1868836914.USD","LU1868837300.USD","IE0002270589.USD","LU2237438978.USD","LU2750360641.GBP","IE00B19Z3B42.SGD","LU1791807156.HKD","LU1804176565.USD","LU0096364046.USD","LU1868837136.USD","LU2237443978.SGD","BK4550","LU0048573561.USD","IE00BSNM7G36.USD","BK4534","BK4219","BK4533","IE0004091025.USD","LU2471134523.USD","LU0061475181.USD","AMT","LU0251142724.SGD","IE00BFXG1179.USD","IE00B19Z3581.USD","LU2237443895.HKD"],"gpt_icon":0},{"id":"2570078576","title":"Uniqure N.V.盘中异动 早盘急速拉升7.41%报51.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570078576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570078576?lang=zh_cn&edition=full","pubTime":"2025-09-25 21:31","pubTimestamp":1758807070,"startTime":"0","endTime":"0","summary":"北京时间2025年09月25日21时31分，Uniqure N.V.股票出现波动，股价快速拉升7.41%。截至发稿，该股报51.02美元/股，成交量206.269万股，换手率3.76%，振幅2.88%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.02%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。消息层面，截至21时31分，《坎托·菲茨杰拉德维持uniQure NV买入评级，维持目标价47美元》资讯为影响Uniqure N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925213111a69dccf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925213111a69dccf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"1107670505","title":"生物技术公司UniQure股价为何一日暴涨两倍，并带动ClearPoint股价一同飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1107670505","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107670505?lang=zh_cn&edition=full","pubTime":"2025-09-25 07:39","pubTimestamp":1758757153,"startTime":"0","endTime":"0","summary":"UniQure还与Hercules Capital签订了一项1.75亿美元的定期贷款协议以支持可能的疗法上市。ClearPoint Neuro通过其称为SmartFlow Cannula的医疗设备为大脑和脊柱的基因疗法提供导航，UniQure使用的正是该技术。Schock表示，UniQure预计最初将在美国瞄准约6,000名可治疗患者。Schock表示，如果获得批准，B. Riley Securities预计UniQure的AMT-130将推动诊断率的提高，可能使确诊人数翻倍。今年以来，ClearPoint Neuro股价上涨了25%，而UniQure的股价上涨了169%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/c2ddfdc2480af7e7bfd27e5cd2b9d3c2","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c2ddfdc2480af7e7bfd27e5cd2b9d3c2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"生物技术公司UniQure股价为何一日暴涨两倍，并带动ClearPoint股价一同飙升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","CLPT"],"gpt_icon":0},{"id":"2569764700","title":"美股异动 | 亨廷顿病关键研究取得积极进展 uniQure(QURE.US)暴涨超186%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569764700","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569764700?lang=zh_cn&edition=full","pubTime":"2025-09-24 22:29","pubTimestamp":1758724195,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9月24日，该公司宣布与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000万美元债务再融资，额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该公司公布AMT-130在亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓75%cUHDRS测量，同时关键次要终点TFC测量显示疾病进展减缓60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 亨廷顿病关键研究取得积极进展 uniQure(QURE.US)暴涨超186%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2569767126","title":"Uniqure N.V.盘中异动 早盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569767126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569767126?lang=zh_cn&edition=full","pubTime":"2025-09-22 23:07","pubTimestamp":1758553653,"startTime":"0","endTime":"0","summary":"北京时间2025年09月22日23时07分，Uniqure N.V.股票出现异动，股价急速上涨5.08%。截至发稿，该股报14.58美元/股，成交量51.9787万股，换手率0.95%，振幅5.78%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.75%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922230734a43cb323&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922230734a43cb323&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"2568528645","title":"Uniqure N.V.盘中异动 股价大涨5.01%报14.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568528645","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568528645?lang=zh_cn&edition=full","pubTime":"2025-09-19 03:08","pubTimestamp":1758222500,"startTime":"0","endTime":"0","summary":"北京时间2025年09月19日03时08分，Uniqure N.V.股票出现异动，股价快速上涨5.01%。截至发稿，该股报14.87美元/股，成交量75.5971万股，换手率1.38%，振幅4.91%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.17%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。消息层面，截至03时08分，《瑞穗证券维持uniQure NV买入评级，维持目标价30美元》资讯为影响Uniqure N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919030821a728cb66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919030821a728cb66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2558662355","title":"Uniqure N.V.盘中异动 下午盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558662355","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558662355?lang=zh_cn&edition=full","pubTime":"2025-08-12 01:33","pubTimestamp":1754933600,"startTime":"0","endTime":"0","summary":"北京时间2025年08月12日01时33分，Uniqure N.V.股票出现异动，股价大幅拉升5.05%。截至发稿，该股报13.95美元/股，成交量44.494万股，换手率0.81%，振幅7.61%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.27%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081201332194dd1794&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081201332194dd1794&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2556882636","title":"Uniqure N.V.2025财年第二财季实现净利润-37.72百万美元，同比增加33.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556882636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556882636?lang=zh_cn&edition=full","pubTime":"2025-08-03 00:01","pubTimestamp":1754150470,"startTime":"0","endTime":"0","summary":"8月3日，Uniqure N.V.公布财报，公告显示公司2025财年第二财季净利润为-37.72百万美元，同比增加33.00%；其中营业收入为5.26百万美元，同比减少52.74%，每股基本收益为-0.69美元。从资产负债表来看，Uniqure N.V.总负债5.89亿美元，其中短期债务3.91百万美元，资产负债比为1.00，流动比率为0.10。机构评级：截至2025年8月3日，当前有12家机构对Uniqure N.V.目标价做出预测，其中目标均价为34.33美元，其中最低目标价为13.00美元，最高目标价为70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000131a6cf7808&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000131a6cf7808&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE"],"gpt_icon":0},{"id":"1145332547","title":"异动解读 | 财报亮点凸显，uniQure盘中大涨10.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145332547","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145332547?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:02","pubTimestamp":1753884128,"startTime":"0","endTime":"0","summary":"基因治疗领域领导者uniQure N.V.周三盘中股价大涨10.81%，引发市场广泛关注。这一显著涨幅与公司最新发布的2025财年第二季度财报密切相关。根据财报显示，尽管uniQure 2025财年前六个月累计收入为682.90万美元，较去年同期的1961.10万美元下降了65.18%，但公司在控制成本方面取得了显著进展。累计净亏损从去年同期的1.22亿美元大幅收窄至8135.60万美元，同比减少33.27%。尽管面临收入下滑的挑战，但净亏损的显著收窄被市场解读为公司正朝着盈利的方向稳步前进。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"gpt_icon":0},{"id":"1141696627","title":"异动解读 | uniQure股价盘中大涨10.81%，Q2财报净亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1141696627","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141696627?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:01","pubTimestamp":1753884117,"startTime":"0","endTime":"0","summary":"周三盘中，基因治疗公司uniQure N.V.股价大涨10.81%，引发市场广泛关注。这一显著涨幅与公司近期发布的2025财年第二季度财报密切相关。尽管收入同比下降，但公司净亏损的大幅收窄似乎赢得了投资者的青睐。然而，公司在控制成本方面取得了显著进展，累计净亏损从去年同期的1.22亿美元收窄至8135.60万美元，同比减少33.27%。尽管面临收入下滑的挑战，但净亏损的显著收窄可能被市场解读为公司正朝着盈利的方向稳步前进。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"gpt_icon":0},{"id":"1127169791","title":"异动解读 | uniQure股价盘前大涨8.26%，Q2财报显示净亏损同比缩小33.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127169791","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127169791?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:24","pubTimestamp":1753863867,"startTime":"0","endTime":"0","summary":"基因治疗公司uniQure N.V.今日盘前股价大涨8.26%，引起市场广泛关注。这一显著涨幅与公司刚刚发布的2025财年第二季度财报密切相关。尽管收入同比下降，但公司净亏损的大幅收窄似乎赢得了投资者的青睐。然而，公司在控制成本方面取得了显著进展，累计净亏损从去年同期的1.22亿美元收窄至8135.60万美元，同比减少33.27%。尽管面临收入下滑的挑战，但净亏损的显著收窄可能被市场解读为公司正朝着盈利的方向稳步前进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"gpt_icon":0},{"id":"2555152016","title":"美股财报 | uniQure发布Q2财报 前半年累计净亏损同比缩小33.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555152016","media":"同花顺iNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555152016?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:00","pubTimestamp":1753862408,"startTime":"0","endTime":"0","summary":"uniqure发布Q2财报，2025财年前六月累计收入682.90万美元，去年同期累计收入为1961.10万美元，同比减少65.18%。2025财年前六月累计净亏损8135.60万美元，去年同期累计净亏损为1.22亿美元，同比缩小33.27%。uniqure N.V.作为私人有限责任公司于2012年1月9日依照荷兰相关法律条文成立。uniqure公司在基因疗法领域是领导者，同时研发了第一个也是迄今为止唯一一个得到欧盟监管认可的基因疗法产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730160558a46b2390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730160558a46b2390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":-0.0363},{"period":"1month","weight":0.102},{"period":"3month","weight":-0.6578},{"period":"6month","weight":0.4145},{"period":"1year","weight":0.5591},{"period":"ytd","weight":-0.1015}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"uniQure N.V.作为私人有限责任公司于2012年1月9日依照荷兰相关法律条文成立。公司是一家专业从事基因治疗的生物技术企业，致力于为罕见病和重病患者开发单一治疗途径。其管线包括针对亨廷顿病、与SOD1突变相关的肌萎缩性侧索硬化症、难治性中位颞叶癫痫和法布里病的临床候选药物，反映了对推进基因治疗领域创新疗法的关注。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.013284},{"month":2,"riseRate":0.545455,"avgChangeRate":0.064233},{"month":3,"riseRate":0.25,"avgChangeRate":-0.054124},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure N.V.","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供uniQure N.V.(QURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"uniQure N.V.,QURE,uniQure N.V.股票,uniQure N.V.股票老虎,uniQure N.V.股票老虎国际,uniQure N.V.行情,uniQure N.V.股票行情,uniQure N.V.股价,uniQure N.V.股市,uniQure N.V.股票价格,uniQure N.V.股票交易,uniQure N.V.股票购买,uniQure N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供uniQure N.V.(QURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}